| Literature DB >> 35566498 |
Lung-Hui Tsai1,2, Ching-Chung Chen3, Chien-Ju Lin1, Sheng-Pei Lin1, Ching-Ying Cheng1,2, Hsi-Pao Hsieh4.
Abstract
PURPOSE: According to previous studies, the prevalence rate of cataracts has increased in recent years. This study aims to investigate and analyze the risk factors of early-onset cataracts in Taiwan.Entities:
Keywords: Depression Anxiety Stress Scales; ROS analysis; early-onset cataract
Year: 2022 PMID: 35566498 PMCID: PMC9101402 DOI: 10.3390/jcm11092374
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Patient gender and age characteristics for each experimental group.
| Number | % | Gender | Number | Average of Age | |
|---|---|---|---|---|---|
| Control group | 27 | 38.0% | Male | 12 | 45.17 ± 9.722 |
| Female | 15 | 44.60 ± 4.388 | |||
| Early-onset cataract | 20 | 28.2% | Male | 12 | 49.92 ± 3.679 |
| Female | 8 | 49.75 ± 4.464 | |||
| Combined group | 24 | 33.8% | Male | 9 | 49.33 ± 3.536 |
| Female | 15 | 49.40 ± 6.390 |
Figure 1Family history disease prevalence between each group under controlling of age variance.
Health status analysis using Pearson χ2 for each group.
| Controlling | Groups | Pearson χ2 |
| |||
|---|---|---|---|---|---|---|
| Normal | Cataract | Combined | ||||
| Hypertension | yes | 0 | 7 | 6 | 10.495 | 0.00 ** |
| 0.0% | 35.0% | 25.0% | ||||
| no | 27 | 13 | 18 | |||
| 100.0% | 65.0% | 75.0% | ||||
| Diabetes | yes | 0 | 3 | 4 | 4.799 | 0.05 * |
| 0.0% | 15.0% | 16.7% | ||||
| no | 27 | 17 | 20 | |||
| 100.0% | 85.0% | 83.3% | ||||
| Asthma | yes | 1 | 1 | 1 | 0.048 | 0.98 |
| 3.7% | 5.0% | 4.2% | ||||
| no | 26 | 19 | 23 | |||
| 96.3% | 95.0% | 95.8% | ||||
| Hyperlipidemia | yes | 0 | 2 | 0 | 5.248 | 0.04 * |
| 0.0% | 10.0% | 0.0% | ||||
| no | 27 | 18 | 24 | |||
| 100.0% | 90.0% | 100.0% | ||||
| Immune system disease | yes | 1 | 1 | 1 | 0.048 | 0.98 |
| 3.7% | 5.0% | 4.2% | ||||
| no | 26 | 19 | 23 | |||
| 96.3% | 95.0% | 95.8% | ||||
| Cancer | yes | 1 | 0 | 1 | 0.817 | 0.66 |
| 3.7% | 0.0% | 4.2% | ||||
| no | 26 | 20 | 23 | |||
| 96.3% | 100.0% | 95.8% | ||||
| High myopia | yes | 10 | 12 | 8 | 3.665 | 0.16 |
| 37.0% | 60.0% | 33.3% | ||||
| no | 17 | 8 | 16 | |||
| 63.0% | 40.0% | 66.7% | ||||
| High astigmatism | yes | 1 | 2 | 0 | 2.725 | 0.26 |
| 3.7% | 10.0% | 0.0% | ||||
| no | 26 | 18 | 24 | |||
| 96.3% | 90.0% | 100.0% | ||||
| Thyroid dysfunction | yes | 1 | 2 | 2 | 0.788 | 0.67 |
| 3.7% | 10.0% | 8.3% | ||||
| no | 26 | 18 | 22 | |||
| 96.3% | 90.0% | 91.7% | ||||
| Galactosemia | yes | 0 | 1 | 0 | 2.586 | 0.27 |
| 0.0% | 5.0% | 0.0% | ||||
| no | 27 | 19 | 24 | |||
| 100.0% | 95.0% | 100.0% | ||||
| Homo cystinuria | yes | 0 | 0 | 1 | 1.986 | 0.37 |
| 0.0% | 0.0% | 4.2% | ||||
| no | 27 | 20 | 23 | |||
| 100.0% | 100.0% | 95.8% | ||||
| Migraine | yes | 3 | 4 | 6 | 1.692 | 0.43 |
| 11.1% | 20.0% | 25.0% | ||||
| no | 24 | 16 | 18 | |||
| 88.9% | 80.0% | 75.0% | ||||
| Irritable Bowel Disorder | yes | 2 | 0 | 2 | 1.683 | 0.43 |
| 7.4% | 0.0% | 8.3% | ||||
| no | 25 | 20 | 22 | |||
| 92.6% | 100.0% | 91.7% | ||||
| Chronic pain | yes | 0 | 3 | 1 | 5.009 | 0.04 * |
| 0.0% | 15.0% | 4.2% | ||||
| no | 27 | 17 | 23 | |||
| 100.0% | 85.0% | 95.8% | ||||
| Head injury | yes | 1 | 2 | 1 | 1.004 | 0.61 |
| 3.7% | 10.0% | 4.2% | ||||
| no | 26 | 18 | 23 | |||
| 96.3% | 90.0% | 95.8% | ||||
| Other illnesses | yes | 3 | 8 | 9 | 6.299 | 0.04 * |
| 11.1% | 40.0% | 37.5% | ||||
| no | 24 | 12 | 15 | |||
| 88.9% | 60.0% | 62.5% | ||||
* p < 0.05, ** p < 0.01.
Pearson χ2 analysis on the health status between groups.
| Controlling | Groups | Pearson χ2 |
| |||
|---|---|---|---|---|---|---|
| Normal | Cataract | Combined | ||||
| Steroid | yes | 1 | 2 | 2 | 1.291 | 0.53 |
| 3.7% | 10.0% | 8.3% | ||||
| no | 26 | 18 | 22 | |||
| 96.30% | 90.00% | 91.70% | ||||
| Anti-hypertensive drug pressure | yes | 0 | 7 | 5 | 10.420 | 0.00 ** |
| 0.0% | 35.0% | 20.8% | ||||
| no | 27 | 13 | 19 | |||
| 100.0% | 65.00% | 79.20% | ||||
| Amiodarone | yes | 0 | 1 | 0 | 2.586 | 0.27 |
| 0.0% | 5.0% | 0.0% | ||||
| no | 27 | 19 | 24 | |||
| 100.0% | 95.0% | 100.0% | ||||
| Antihistamine | yes | 1 | 4 | 1 | 4.804 | 0.05 |
| 3.7% | 20.0% | 4.2% | ||||
| no | 26 | 16 | 23 | |||
| 96.3% | 80.0% | 95.8% | ||||
| Hormone therapy | yes | 1 | 0 | 1 | 0.817 | 0.67 |
| 3.7% | 0.0% | 4.2% | ||||
| no | 26 | 20 | 23 | |||
| 96.3% | 100.0% | 95.8% | ||||
| Painkiller | yes | 1 | 3 | 4 | 2.523 | 0.28 |
| 3.7% | 15.0% | 16.7% | ||||
| no | 26 | 17 | 20 | |||
| 96.3% | 85.0% | 83.3% | ||||
| Other drugs | yes | 4 | 7 | 6 | 9.991 | 0.01 * |
| 14.8% | 35.0% | 25.0% | ||||
| no | 23 | 13 | 18 | |||
| 85.2% | 65.0% | 75.0% | ||||
* p < 0.05, ** p < 0.01.
Figure 2Psychological status of DASS-42 between each group.
Pearson χ2 analysis of blood results between each group.
| Controlling | Groups | Pearson χ2 |
| |||
|---|---|---|---|---|---|---|
| Normal | Cataract | Combined | ||||
| GPx index | normal | 12 | 7 | 13 | 1.267 | 0.53 |
| 80.0% | 77.8% | 92.9% | ||||
| abnormal | 3 | 2 | 1 | |||
| 20.0% | 22.2% | 7.1% | ||||
| CRP index | normal | 15 | 7 | 8 | 7.856 | 0.02 * |
| 100.0% | 70.0% | 57.1% | ||||
| abnormal | 0 | 3 | 6 | |||
| 0.0% | 30.0% | 42.9% | ||||
| TAC index | normal | 10 | 7 | 12 | 1.512 | 0.47 |
| 66.7% | 70.0% | 85.7% | ||||
| abnormal | 5 | 3 | 2 | |||
| 33.3% | 30.0% | 14.3% | ||||
* p < 0.05; total antioxidative capacity, TAC; C-reactive protein, CRP; glutathione peroxidase, GPx.
Multinomial logistic regression analysis in each dimension (controlling age variance).
| Dimension | χ2 |
| Cox R2 |
|---|---|---|---|
| Background | 9.889 | 0.042 | 0.125 |
| Family disease | 35.470 | 0.003 | 0.341 |
| Healthy status | 48.972 | 0.000 | 0.438 |
| Medication | 39.619 | 0.001 | 0.373 |
| Psychology | 13.510 | 0.009 | 0.149 |
| Blood | 7.452 | 0.024 | 0.170 |
| Eye examination | 18.685 | 0.001 | 0.215 |
| Overall | 72.990 | 0.004 | 0.883 |
Multinomial logistic regression analysis between each group.
|
| S.E. | Wald | Exp(B) | |||
|---|---|---|---|---|---|---|
| BMI | EOC vs. Control | −1.043 | 0.606 | 2.961 | 0.085 | 0.352 |
| Combined vs. Control | −1.873 | 0.648 | 8.357 | 0.004 ** | 0.154 | |
| Educational level | EOC vs. Control | −1.456 | 0.733 | 3.949 | 0.047 * | 0.233 |
| Combined vs. Control | −1.755 | 0.730 | 5.785 | 0.016 * | 0.173 | |
| Family heart disease | EOC vs. Control | −2.165 | 0.987 | 4.812 | 0.028 * | 0.115 |
| Combined vs. Control | −1.456 | 1.025 | 2.018 | 0.155 | 0.233 | |
| Family hypertension | EOC vs. Control | −1.420 | 0.651 | 4.760 | 0.029 * | 0.242 |
| Combined vs. Control | −0.780 | 0.620 | 1.580 | 0.209 | 0.459 | |
| Family allergies | EOC vs. Control | −1.133 | 0.772 | 2.155 | 0.142 | 0.322 |
| Combined vs. Control | −1.679 | 0.775 | 4.699 | 0.030 * | 0.187 | |
| High myopia | EOC vs. Control | −1.950 | 0.758 | 6.625 | 0.010 * | 0.142 |
| Combined vs. Control | −1.442 | 0.616 | 5.515 | 0.019 * | 0.143 | |
| Other illness | EOC vs. Control | −1.900 | 0.830 | 5.235 | 0.022 * | 0.150 |
| Combined vs. Control | −1.697 | 0.732 | 5.367 | 0.021 * | 0.183 | |
| Other drugs | EOC vs. Control | −1.677 | 0.880 | 3.635 | 0.057 | 0.187 |
| Combined vs. Control | −1.303 | 0.795 | 2.684 | 0.101 | 0.272 | |
| Stress | EOC vs. Control | 1.182 | 0.504 | 5.505 | 0.019 * | 3.259 |
| Combined vs. Control | 0.850 | 0.480 | 3.131 | 0.077 | 2.339 | |
| CRP | EOC vs. Control | 6.307 | 3.689 | 2.923 | 0.087 | 548.43 |
| Combined vs. Control | 6.337 | 3.657 | 3.003 | 0.083 | 565.38 | |
| BCVA | EOC vs. Control | −12.207 | 5.620 | 4.718 | 0.030 * | 0.005 |
| Combined vs. Control | −7.811 | 5.994 | 1.698 | 0.193 | 0.033 | |
| Spherical equivalent | EOC vs. Control | 0.339 | 0.149 | 5.181 | 0.023 * | 1.404 |
| Combined vs. Control | 0.242 | 0.106 | 5.202 | 0.023 * | 1.274 | |
* p < 0.05, ** p < 0.01; body mass index (BMI); C-reactive protein (CRP); best corrective visual acuity (BCVA).